A gradual shift underway in Canada where biosimilars have been slowly catching on.
Biosimilars are steadily gaining ground in Canada. Johnson & Johnson’s Remicade, a blockbuster drug that treats autoimmune disorders, has steadily lost market-share among patients enrolled in the Canadian province of Quebec’s public drug program.
The province's drug plan stopped reimbursement of Remicade in lieu of available biosimilars. Despite a subsequent court ruling that reinstated the reimbursement of the biologic, Remicade’s eroding market share underscores a gradual shift underway in Canada where biosimilars are slowly catching on with doctors and patients.
Though Canada has about 2% of global drug sales, the country had 16% of Remicade sales in 2017, about C$1 billion ($755.8 million), according to the country’s Competition Bureau.
In May, the province of British Columbia said it would require thousands of patients on its public drug plan to switch to biosimilars. Health Canada says biosimilars are just as safe and effective, but drugmakers and patient groups have pushed back.